Back
The efficacy of triglyceride/high-density lipoprotein cholesterol (TG/HDL- C) and non-high-density lipoprotein cholesterol/ high-density lipoprotein cholesterol (non-HDL-C/HDL-C) ratios had been demonstrated as predictor of adverse cardiovascular events and mortality predictors on healthy patients. However, limited studies have been performed to evaluate the efficacy of TG/HDL-C and non-HDL-C/HDL-C ratios as mortality predictors in hemodialysis patients.
A transversal, retrospective, case-control study was developed. A total of 386 patients with treatment of end stage kidney disease on hemodialysis therapy in Hemodialysis Unit of National Medical Center XXI Century from January of 2019 to December of 2022 were enrolled. The medical records, albumin levels, calcium, hemoglobin, parathyroid hormone (PTH), total cholesterol, HDL-C, LDL-C, triglyceride, TG/HDL- C and non-HDL-C/HDL-C were registered. The odds ratio was calculated using chi-square and student´s t-test, considering a p > 0.05 as a statistically significant value. The prognostic values were accessed by univariate and multivariate COX regression analysis.
A total of 386 patients were enrolled. They were distributed as 288 control patients (living) and 98 case patients (dead). The multivariate Cox regression analysis showed that patients over 60 years old (2.19, CI 95%, 1.52-3.17 p <0.001), and a TG/HDL- C index >3.29 were strongly correlated with increased risk of death (1.648, CI 95%, 1.029-2.638, p 0.038). In contrast, the treatment of dyslipidemia was associated with reduction on the risk of death (0.298, CI 95%, 0.160-0.553, p <0.001).
The TG/HDL-C ratio have potential as predictor of mortality in hemodialysis patients. The non-HDL-C/HDL-C ratio failed as prognostic tool, with no statistically significant results in the analysis.